Provenance Wealth Advisors’s Moderna MRNA Stock Holding History

Provenance Wealth Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.54K	Buy	+22	New	+$1.14K	﹤0.01%	470

Other funds holding MRNA

BPC

Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

OIAM

OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return

LSA

Leonteq Securities AG Zurich, Switzerland $2.91B AUM 56.5% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

TFCP

Twin Focus Capital Partners Boston, Massachusetts $983M AUM 37.07% 1-Year Est. Return

Provenance Wealth Advisors's MRNA Position: Q2 2026 in Review

Provenance Wealth Advisors opened a new position in Moderna (MRNA) in Q2 2026: 22 shares worth $1.54K. The stake represents ﹤0.01% of the portfolio and ranks #470 among its holdings.

273 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Provenance Wealth Advisors held 22 shares of Moderna worth $1.54K as of Q2 2026.
Moderna was a new Provenance Wealth Advisors position in Q2 2026.
Moderna made up ﹤0.01% of Provenance Wealth Advisors's portfolio in Q2 2026, its #470 holding.
273 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Provenance Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.